(A) Schematic representation of the miR-9 MO binding to microRNA-9. With the control MO, miR-9 is available, allowing the degradation of the mRNA target and revealing the miR-9 expression pattern with the specific miR-9 LNA probe. In presence of the miR-9 MO, miR-9 is bound by the MO, inhibiting the mRNA degradation and the binding of the LNA probe. (B) Whole-mount in situ hybridization against miR-9 at 72 hpf shows that miR-9 knockdown does not affect trunk morphogenesis.mCherry immunolabelling in Tg(kdrl:mCherry) at 72 hpf showing blood vessels formation in the trunk of control or miR-9 morphant larvae. In the trunk, miR-9 knockdown does not affect blood vessels development. (C) Confocal projections of mCherry immunolabelling in Tg(kdrl:mCherry) at 72
hpf showing blood vessels formation in control or miR-9 morphant larvae in the brain. The affected neurovasculature in the midbrain, hindbrain and retina is highlighted by an asterisk. (D, E) Whole-mount in situ hybridization against miR-9 at 72 hpf in larvae injected with the control MO or the miR-9 MO in the retina (D) and brain (E). Confocal projections of mCherry immunolabelling in Tg(kdrl:mCherry) at 72 hpf showing blood vessels formation in control MO and miR-9 MO injected larvae. Higher is the quantity of miR-9 MO injected in the egg, stronger is inhibition of miR-9 expression. The severity of the neurovasculature defects is correlated to the level of miR-9 inhibition. (F) The formation of the hyaloid vasculature in the retina of control MO (n=25) or miR-9 MO dilution series (n=24, 30 and 28 for croissant dilutions respectively) at 72 hpf was classified in four groups and quantified. Group 1: The blood vessels form a complex vascular network. Group 2: The hyaloid vasculature shows a reduced branching complexity. Group 3: In addition to the reduction of the branching, the caliber is affected and some vessels appear to be thicker. Group 4: The hyaloid vasculature is absent. Dorsal view of the brain with anterior up. Lateral view of the retina. Box1 is a close up of the retina. Box2 is a close up of the hindbrain. Box3 is a close up of the hyaloid vasculature in the retina. Scale bars: 10 µm for immunolabelling and 100 µm for whole mount ISH. Figure 3) (A, B) Whole-mount in situ hybridization against tlx (A) or ocl (B) in larvae at 72 hpf injected with the control MO, the miR-9 MO or the miR-9 RNA mimic. tlx and ocl behave like a miR-9 target showing an increase in the miR-9 knockdown and a decrease in the miR-9 gain of function. (C, D) Schematic representation of the zebrafish oc1 (C) and oc2 (D) mRNA indicating the sequence of the putative miR-9 binding sites in the 3'UTR (red). Whole-mount in situ hybridization against oc1 (C) and oc2 (D) in larvae at 72 hpf injected with the control MO, the miR-9 MO or the miR-9 RNA mimic. onecut family mRNAs behave like miR-9 targets showing an increase in the miR-9 knockdown and a decrease in the miR-9 gain of function. (E, F) Fluorescent sensor assay to test the functionality of miR-9 binding sites in the 3'UTR of oc1 (E) and ocl (F) showing that miR-9 mediates oc1 and ocl inhibition via the 3'UTR. TagRFP and EGFP protein expression in embryos at 24 hpf: embryos were co-injected with the egfp mRNA containing the 3'UTR of oc1 (n=7) or ocl (n=3) fused to the SV40pA and the internal control, tagrfp mRNA (n=8 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES Primary human embryonic neural stem cells culture, purification and transfection
Human fetal cortex was collected after elective abortion by a commercial vendor (StemExpress, Placervill, CA). The meninges were removed and the tissue was enzymatically dissociated to make a suspension of single cells as described previously (Cahoy et al., 2008; Dugas et al., 2006) . Briefly, the tissue was incubated at 33°C for 45 minutes in 20 ml of a papain solution containing Earle's balanced salts (EBSS, Sigma, St. Louis, MO, E7510), D(+)-glucose (22.5mM), NaHCO3 (26mM), DNase (125U/ml, Worthington, Lakewood, NJ, LS002007), papain (4 U/ml, Worthington, Lakewood, NJ, LS03126), and L-cysteine (1mM, Sigma, St. Louis, MO, C7880). The papain solution was equilibrated with 5% CO2 and 95% O2 gas before and during papain treatment. Following papain treatment, the tissue was washed three times with 4.5ml of inhibitor buffer containing BSA (1.0mg/ml, Sigma, St. Louis, MO, A-8806), and ovomucoid (also known as trypsin inhibitor, 1.0 mg/ml, Roche Diagnostics Corporation, Indianapolis, IN 109878) and then mechanically dissociated by gentle sequential trituration using a 5ml pipette. Dissociated cells were layered on top of 10ml of high concentration inhibitor solution with 5mg/ml BSA and 5mg/ml ovomucoid and centrifuged at 130g for 5 minutes. The cell pellet was then resuspended in 12 ml Dulbecco's phosphate-buffered saline (DPBS, Invitrogen, Carlsbad, CA 14287) containing 0.02% BSA and 12.5U/ml DNase and filtered through a 20um Nitex mesh (Sefar America Inc., Depew NY, Lab Pak 03-20/14) to remove undissociated cell clumps. Cell health was assessed by trypan blue exclusion.
To purify neural stem cells, the single cell suspension was immunopanned with a CD15 antibody (BD, mouse) for a 30 minute incubation. The adherent cells on the CD15 plate were washed 8 times with 10-20 ml of DPBS to remove all antigen-negative nonadherent cells, and then removed from the plate by treating with trypsin (Sigma, 1,000U/ml, T-4665) in 8ml Ca 2+ and Mg 2+ free EBSS (Irvine Scientific, Santa Ana, CA, 9208) for 3-10 minutes at 37°C in a 10% CO2 incubator. The cells were dislodged by gentle squirting of over the plate and harvested by centrifugation at 200g for 10 minutes.
Plasmid transfection was performed on purified neural stem cells from 14 week-old human fetal brains. TLX and ONECUT2 ORF were amplified by PCR from human cDNA, fused to the p2A-EGFP and cloned in the pCDNA3.1 vector downstream of a CMV promoter. EGFP, TLX, and OC2 plasmids were transfected into cells using the nucleofector kit (Lonza) for primary neural stem cells. 2-4ug of each plasmid was added to the cell suspension and briefly electoporated according to the user protocol. Cells were then plated on PDL coated coverslips and cultured in a defined media including DMEM, insulin, pyruvate, Pen/Strep, L-glutamine, Sato, and Nacetylcysteine. Two 14 week-old brains were used to prepare 6 samples for each condition, each sample containing 150-450 cells.
Generation of human iPSC-derived cortical neurons
Human iPSCs derived from healthy individuals were grown on inactivated mouse embryonic fibroblasts feeders in iPSC medium (DMEM/F12, 20% Knockout Serum, 1mM non-essential amino acids, GlutaMax (1:200), 0.1mM β-mercaptoethanol, penicillin and streptomycin (1:100)). Colonies of iPSCs were detached with dispase (0.35mg/ml, Invitrogen) and transferred into low-attachment plates in iPSC medium supplemented with dorsomorphin (5 μM, Sigma) and SB-431542 (10 μM, Tocris), and the medium was changed daily. On day six of in vitro differentiation, neural spheroids were transferred to neural medium (NM) (Neurobasal A, B27 without vitamin A, GlutaMax (1:100), penicillin and streptomycin (1:100); Life Technologies), which was supplemented with EGF (20 ng/ml) and FGF2 (20 ng/ml) until day 24, and then supplemented with BDNF (20 ng/ml) and NT3 (20 ng/ml) from day 25 to 42. From day 43 onwards, cortical spheroids were maintained in NPC with medium changes every 4 days.
For enzymatic dissociation and culture in monolayer (Deverman et al., 2016) , hCS were incubated with accutase for 15 minutes at 37°C, washed 3 times with NM and gently triturated with a P-200 pipet. Cells were plated on poly-ornithine and laminin coated glass coverslips (15 mm) at around 300,000 cells/well and maintained in NM supplemented with BDNF (20 ng/ml) and NT3 (20 ng/ml) with half medium changes every other day.
Zebrafish transgenic lines and plasmid construction
The following transgenic lines were used to visualize: post-mitotic neurons Tg(huc:egfp) (Park et al., (Chi et al., 2008) and Tg(kdrl:egfp) (Choi et al., 2007a) .
2000), neural stem cells Tg(gfap:gal4); Tg(uas:egfp), miR-9 expressing cells Tg(CNE1:egfp), referred as Tg(hsa-MIR-9-2:egfp) or endothelial cells Tg(kdrl:ras-mCherry)
For the generation of Tg(alpha-tubulin:gal4) and Tg(gfap:gal4), the goldfish a1-tubulin promoter (Hieber et al., 1998) and the zebrafish gfap promoter (Bernardos and Raymond, 2006) were cloned into the p5E 5' entry vector of the tol2kit (Kwan et al., 2007) . Then, the 5' entry vector was recombined into the Tol2 transposon destination vector. pTol2-vegfaa:egfp was by made by PCR amplification of 1.5kb upstream of the vegfaa promoter from zebrafish genomic DNA. PCR products were directionally cloned into the XhoI and BglII sites of the pTol2-E1b:EGFP vector. To establish Tg (alpha-tubulin:gal4) , Tg(gfap:gal4) and Tg(CNE1:egfp) stable transgenic lines, plasmids were injected into one-cell stage embryos with the Tol2 mRNA transposase (Kwan et al., 2007) .
To generate pDestTol2 p2A-egfp plasmids for transient expression; vegfaa, tlx and ocl ORF were amplified by PCR from zebrafish cDNA and cloned in the pME entry vector of the tol2kit. The appropriate middle entry clone was mixed with the UAS or the heat-shock promoter 5' entry vector and the SV40pA 3' entry vector, and recombined into the Tol2 transposon destination vector (Kwan et al., 2007) .
In situ hybridization
In situ hybridizations were performed as previously described (Oxtoby and Jowett, 1993) . Previously described antisense DIG labelled probes for neurog1 (Blader et al., 1997) , deltaA (Haddon et al., 1998) , ascl1a and ascl1b (Allende and Weinberg, 1994) were generated using standard procedures. ORFs were cloned in a pCS2+ vector using zebrafish cDNA for vegfaa, tlx, oc1, oc2, and ocl or human cDNA for SOX2; and antisense DIG labelled probes were transcribed using the linearized pCS2+ plasmid containing the ORF. For miR-9 ISH, the previously described miRCURY detection probe (LNA) hsa-miR-9 (Exiqon) was used (Leucht et al., 2008) . In situs were revealed using either BCIP and NBT (Roche) or Fast Red (Roche) as substrates.
Antisense morpholino and microRNA-9 mimic injection
We used the previously described miR-9 MO (TCATACAGCTAGATAACCAAAGA) and the control MO (CACCAAACCATATAGAAGTGATA) (Leucht et al., 2008) . Embryos were injected at the one-cell stage with 0.12 to 2 pmole of the miR-9 or control MO. tlx (GCTTGCTCATATTGAAGACCACGGC) and ocl (ACATCTCTCCCATATTACCATCCAT) MOs were injected at 1 pmole and the efficiency of the MO was tested by the capacity of the MO to down-regulate EGFP (but not the internal mCherry control) expression driven by a construct containing the MO binding site in the 5'UTR of tlx or ocl fused to a p2A-EGFP (data not shown). For target protection, tlx TP (CCTTTGGTTTTCAGCACTATGTCAA), ocl TP (TCTTTGGTATTGGGACTCCTATCAG), and control TP (CTGTGGCCTAAAGGGTCTAGACATG) were designed as previously described (Choi et al., 2007b; Staton and Giraldez, 2011 ) and used at 1 pmole.
Gain of function of miR-9 was performed with the injection of the mirVana miR-9 RNA mimic, hsa-miR-9-5 (2 μM, Ambion).
Mosaic analysis
For mosaic expression of uas :vegfaa, uas:tlx, uas:ocl, uas:tlx-p2A-egfp, uas:ocl-p2A-egfp, hs:tlx, hs:ocl, hs:tlx-p2A-egfp and hs:ocl-p2A-egfp, the appropriate Tol2 based construct (25 ng/μl) was co-injected with synthetic mRNA encoding the Tol2 transposase (25ng/μl) into one-cell stage embryos. Heat-shocks were performed in a water bath at 37°C for 1 hour. For pan-neuronal expression using the uas promoter, the injection was performed in embryos from crosses between identified heterozygote carriers of Tg (alpha-tubulin:gal4) and Tg(kdrl:ras-mCherry).
Expression in neural stem cells was performed by injection in the Tg(gfap:gal4) line.
Drug treatments
Tg(kdrl:ras-mCherry) embryos were treated with 0.06 μM solution of the chemical tyrosine kinase inhibitor SU5416 (S8442, Sigma Aldrich) dissolved in DMSO (Herbert et al., 2009) . Treatments started at 30 hpf and both DMSO and SU5416 treated embyos were fixed at 72 hpf to quantify the blood vessels sprouting.
Fluorescent sensor assay
Fluorescent sensor assay with the 3'UTR of oc1 and ocl was performed as described in (Staton and Giraldez, 2011) . Capped mRNAs for EGFP containing the oc1 or ocl 3'UTR and TagRFP reporter constructs were synthetized using linearized pCS2+ plasmids and mMessage mMachine kit (Ambion). Zebrafish embryos were injected at a one-cell stage with 150ng/μL of EGFP and TagRFP mRNAs and either a control or miR-9 RNA mimics (2 μM, Ambion). The ratio of EGFP/TagRFP fluorescence was quantified using ImageJ software.
In silico predictions
Putative targets for miR-9 in human were first searched using the ElMMo miRNA target prediction server (http://www.mirz.unibas.ch/ElMMo3). 3'UTR of orthologous genes in zebrafish were retrieved from the Ensembl web server and searched for conserved miR-9 binding sites (Bartel, 2009 ).
The miR-9 consensus binding sequence (Leucht et al., 2008) was queried against the 3'UTR of each human gene in the GRCh37 human reference (hg19) using LASTZ (version 1.02.00) with sensitive parameters (--hspthresh=500 --gappedthresh=500 --seed=match6). The highest scoring alignments from LASTZ were inspected for conservation using the UCSC 46-way multiple alignment (Karolchik et al., 2014) .
